Zealand Pharma A/S (OTCMKTS:ZLDPF) Upgraded at William Blair

Zealand Pharma A/S (OTCMKTS:ZLDPF) was upgraded by stock analysts at William Blair to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Several other analysts have also weighed in on the company. Cantor Fitzgerald raised Zealand Pharma A/S to a “strong-buy” rating in a research note on Tuesday, January 21st. JPMorgan Chase & Co. initiated coverage on Zealand Pharma A/S in a research note on Friday, November 8th. They issued an “overweight” rating on the stock.

Zealand Pharma A/S Stock Performance

ZLDPF opened at $97.78 on Thursday. The business’s fifty day moving average is $101.00 and its 200-day moving average is $112.64. The firm has a market cap of $6.94 billion, a P/E ratio of -41.43 and a beta of 0.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 35.49 and a current ratio of 35.49. Zealand Pharma A/S has a 52-week low of $80.86 and a 52-week high of $141.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.19. The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $28.11 million. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. Sell-side analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.